Cancer incidence and novel therapies developed in Japan
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According to the ministry of Health, Labour and welfare of Japan, Cancer has been the leading cause of death in Japan since 1981. ^\[[@b1]\]^ As per the data in 2010, in Japan, one in every three deaths was due to cancer. ^\[[@b2]\]^ The Japanese Government has introduced so far, three terms of 10 years strategies for Cancer control since 1984 till date. The budget allocated for cancer control in 2009 was 52.5 billion yen in Japan. ^\[[@b3]\]^ Lung is the leading site for cancer in both males and females in Japan. In males, following the lung, stomach, liver, colon and pancreas are other leading sites while in the females, stomach, colon, pancreas and breast are the other leading sites. ^\[[@b1]\]^ In 2006, the cancer incidence was 694,000 and the male cancer incidence was 1.4 times as large as that of females. The peak age for cancer deaths in males is their fifties while in the females it is the sixties among Japanese. In addition to the conventional treatments such as surgery, radiotherapy and chemotherapy, some of other therapies in practice in Japan are the Hyperthermia ^\[[@b4]\]^ that uses high temperatures to kill or damage the cancer cells, the Ion Beam therapy using proton beams ^\[[@b5]\]^ to damage the DNA of the cells as cancer cells have high rate of cell divisions and lesser ability to repair DNA damage, the molecular targeted therapies that interfere with a specific molecular target involved in tumour growth and progression^\[[@b6]\]^ and most importantly the autologous cell based Immunotherapies.

Modern Cancer Immunotherapy started in the 1970s in Japan. The immunopotentiators using compounds from Bacteria, Beta Glucans from fungi were the first forms of modern Immunotherapy. Then was the era of direct injection of cytokines such as Interleukins, Interferons etc. The adverse effects associated with the injection of cytokines led to development of cell based Immunotherapies in the 1980s. ^\[[@b7]\]^ Immuno-cell therapies involve isolation of immune cells which are then processed and re-injected into the body to exert their action against the cancer. There are different kinds of Immuno-cell therapies being practised in more than 25 private and public institutions in Japan using Natural Killer (NK) cells, Cytotoxic T lymphocytes (CTLs), Tumour Infiltrating Lymphocytes (TIL), Lymphokine activated Killer (LAK) cells, Dendritic cells and Gamma Delta T (γδ T) cells.^\[[@b7]\]^ Importantly most of the innovations in cell based therapies in the world have been made in Japan because immunotherapy is a part of the Japanese Health care system and routine therapies for cancer in Japan. There have been randomized clinical trials on Immuno-cell therapy for liver cancer, lung cancer, gastric cancer, ovarian cancer with the results suggesting statistically significant increase in survival rate and increase in disease free survival rate. ^\[[@b8],\ [@b9],\ [@b10],\ [@b11]\]^ There are more than 25 institutions in Japan performing such cell based immunotherapies. A comprehensive review by Egawa et al on 1401 patients showed that when Immuno-cell therapy was combined with the conventional therapies, the efficacy increased upto 20-30%. ^\[[@b7]\]^ Immuno-cell is the least toxic of all therapies and can be administered even to terminally ill cancer patients. ^\[[@b12]\]^ Contrast to drugs, as autologous cell based Immuno-therapies are from the patient's own blood and as they are custom tailored to each patient, though expensive, the adverse effects are minimal. To conclude, cancer-Immunocell therapies are the future of cancer therapies and further research is needed to enhance its efficacy and validate the results.
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Introduction
============

Cancer, the major killer disease of the century requires a multi-pronged approach and among the latest modalities of treatments, Immunotherapy occupies a promising role. Immunotherapy for cancer was first started to be practised in the NIH and cell based immunotherapy for cancer is in practice for the past three decades. ^\[[@ab1],\ [@ab2]\]^ There are several literatures from various countries on the successful application of cell based Immunotherapies for various solid tumours and haematological malignancies. ^\[[@ab3]-[@ab8]\]^ Our team's association with immune cells started when I was working on RNA transcriptome analysis to understand the immune system in HIV carriers which in turn required *in vitro* expansion of human Natural Killer (NK) cells. ^\[[@ab9]\]^ This led to the customization of protocols which has resulted in successful *in vitro* expansion, activation of NK cells and T cells for Immunotherapy. The purpose of Biotherapy institute of Japan (BIJ) is to support research and clinical application of immune cells like NK cells, γδT cells, αβT cells, Cytotoxic T lymphocytes (CTL) and Dendritic cells (DC) for application as Autologous Immune Enhancement Therapy (AIET) to fight against cancer. AIET using NK cells, CTLs, DCs etc have been administered for more than 5000 patients since 2004 till date by BIJ.

Principle of AIET
=================

For AIET using NK cells, the process involves separation of lymphocytes from the peripheral blood of the patient followed by selective NK cell expansion using the expansion kit (BINKIT, BIJ, JAPAN) without feeder layers and then infusion of the expanded-activated NK cells. ^\[[@ab10],[@ab11]\]^ As reports suggest that the activity of peripheral blood NK cells are lower in cancer patients compared to normal individuals^\[[@ab12]\]^ and as *in vitro* expansion of NK cells increases the cytotoxic ability 5 to 10 fold, ^\[[@ab13]\]^ the NK cells are expanded *in vivo* and then infused to the patient in AIET.

We are also working on combination immunotherapy using NK cells and CTLs and also NK cells and peptide pulsed DCs. The principle behind combining NK cells and CTLs is a dual advantage approach combining the innate immune system and adaptive immune system wherein the CTLs will kill the MHC expressing cancer cells while NK cells will kill the MHC non-expressing cancer cells also. ^\[[@ab10]\]^ In case of NK cells and DCs, DCs will in turn activate the CTLs thereby giving rise to the dual advantage mentioned above. We have recently suggested that the AIET using expanded NK cells, particularly in combination with monoclonal antibody drugs, may be very useful tool for cancer immunotherapy. ^\[[@ab14]\]^

Our experience
==============

In our studies in NOG SCID mice, activated NK cells were shown to reduce the size of breast cancer cells (MDA-MB231) ^\[[@ab15]\]^ and the volume of ascites also inhibiting lung metastasis of pleural effusion lymphoma (PEL) cells. ^\[[@ab16]\]^ In a primary lung adenocarcinoma patient where AIET was administered in combination with Hyperthermia, the CEA values decreased from 4.8 ng/ml to 1.6 ng/ml, the SLX decreased from 30 U/ml to 27 U/ml, the IAP reduced from 300 μg/ml to 221 μg/ml along with resolution of the lung lesions in four months. A 55 year old woman treated for invasive ductal carcinoma of breast presented with metastasis to the lungs. She was then treated with trastuzumab in combination with multiple injections of activated natural killer (NK) cells (at two week intervals) following which the tumor markers decreased. Progression free survival was 10 months. ^\[[@ab11]\]^ Fifty-two patients with advanced cancers in organs like lung, breast, colon, prostate, liver, kidney, ovary etc, refractory to conventional therapy when treated with a combination of hyperthermia and NK cell-and CTL-based immune cell therapy with low-dose chemotherapy, in 18 of 52 patients, objective responses was observed including one complete response (CR) and 17 partial responses (PR) evaluated according to to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. Sixteen patients had stable disease (SD), whereas 18 had progressive disease (PD). Disease control rate was 66% including CR, PR and SD. After treatment for six months, the objective responses and disease control rate were 25% and 52%, respectively. There were no adverse effects in any of these patients. ^\[[@ab17]\]^

Conclusion
==========

Cancer has to be tackled with a multipronged approach and combining NK cell and CTL cell based AIET with conventional modalities of treatments such as Surgery, Chemotherapy and Radiotherapy as well as other modalities like Hyperthermia, Proton Beam therapy and low dose chemotherapy is effective even in advanced cancers which are refractory to conventional therapeutic modalities.

Hurdles overcome in technology transfer for AIET and Positive outcome in Indian patients
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Introduction
============

Cell based immunotherapies have been in practice in Japan for the past two decades with established clinical trials on its efficacy in both solid tumours and hematological malignancies including gastric cancer, ovarian cancer, lung cancer and liver cancer. ^\[[@bb1],[@bb2],[@bb3],[@bb4]\]^ In India, NCRM has been providing Autologous Immune Enhancement Therapy (AIET) using autologous Natural Killer (NK) cells and activated T Lymphocytes for Cancer since 2005 following the established protocols practiced by the Biotherapy Institute of Japan. Significant outcome achieved after AIET in advanced pancreatic cancer, Acute Myeloid leukemia (AML) in Indian patients have already been reported.^\[[@bb5],\ [@bb6]\]^ Here we report our experience in few more patients and present the hurdles overcome and lessons learned in translating the technology from Japan to India

Case Details
============

Case 1
------

A 54 year-old female presented with Stage IV recurrent ovarian malignancy in 2010 with a history of previous surgery and chemotherapy for ovarian malignancy in June 2009. The CA-125 level of 243 U/ml. CT scan revealed lesions in the liver, spleen, along the greater curvature of body of stomach and in the perisplenic region, between the medial aspect of liver and stomach and in the right inguinal region. She was suggested six cycles of chemotherapy with Doxorubicin (50 mg) and Carboplatin (450 mg) along with AIET. After proper informed consent, the peripheral blood was withdrawn and the *in vitro* expansion of the NK cells, activated T Lymphocytes from the peripheral blood was performed using the protocol reported earlier.^\[[@bb7]\]^ Average cell count after the *in vitro* expansion was 1.2 X 10^8^ cells. Six transfusions of the *in vitro* expanded NK cells and activated T lymphocytes were administered following which the CA-125 decreased to 4.7 U/mL. CT scan taken in December 2010 showed a regression of the lesions in the spleen and perisplenic peritoneal deposits, stable hepatic lesions and resolution of perigastric peritoneal deposits with a marked decrease in the size of the inguinal lymph nodes from and no recurrence in the pelvic region. There was also improvement in appetite and quality of life of the patient. There were no adverse reactions following the AIET infusions.^\[[@bb8]\]^ The latest follow-up in May 2012 revealed static non progressive disease with all the parameters including tumor markers within normal range.

Case 2
------

A 15 year old girl presented with complaints of diffuse bone pain for 3 months, intermittent fever for 1 month and increasing pallor in October 2004. On examination, she was found to have pallor with hepatosplenomegaly. A low haemoglobin level (9.3 mg/dl), low platelets (21000) and a WBC count of 13600 with 83% lymphoblasts was revealed in her blood picture. Bone marrow examination and flow cytometry were suggestive of Acute Lymphoblastic Leukemia ‑ CD 10+ CD 19+. Cytogenetics revealed Philadelphia chromosome and BCR-ABL positivity. Qualitative BCR-ABL was done serially to assess disease status. She was started on chemotherapy as per UK MRC protocol ‑ Regimen B along with Imatinib Mesylate (in view of her BCR-ABL positivity) and prophylactic cranial radiotherapy of 12 Gy at the end of delayed intensification. She had persistent disease with low positive BCR-ABL at 0.04% at the end of delayed intensification. As there were no matched HLA donors as she had high risk disease she was suggested for AIET using autologous natural killer (NK) cells (CD3-CD56+) in January 2007. 562 x 10^6^ *in vitro* expanded NK cells were infused to the patient intravenously and four weeks later, the BCR-ABL in the PB turned negative. She completed her treatment in October 2007. She has been on regular follow up for the last five years and she continues to be in remission.

Case 3
------

A female patient aged 64 years with advanced serous papillary Adenocarcinoma of both ovaries with liver metastasis underwent omentectomy and resection of the liver nodule in the month of January 2011 and completed 6 cycles of chemotherapy with Paclitaxel and Carboplatin, completed in April 2011. In April 2011, non-enhancing lesions in the Left lobe of the liver and a left gastric node were revealed in the CT scan of the whole abdomen. The patient was suggested for radiofrequency ablation and maintenance chemotherapy along with AIET. The patient was administered five transfusions of AIET using autologous NK cells and activated T lymphocytes. 140 ml of peripheral blood (PB) was withdrawn in May 2011 from which two transfusions of AIET with the average NK cell count being 618 million and T cell count being 331 million were administered. However when 140 ml of PB was withdrawn for the second time in June 2011 for two more transfusions, the peripheral blood mononuclear cells (PBMNCs) count were alarmingly lower though she had a WBC count of 4600 cells, and the expansion of NK cells, T lymphocytes was not marked following which her report which was received from a Hospital in Thailand revealed that she had Auto-immune Hemolytic anemia (AIHA) for which she was prescribed steroids. It has already been reported that the functional profile of NK cell is lower in AIHA patients.^\[[@bb9]\]^ Also the limiting factor of steroid administration is also to be considered. The average NK cell count of the third and fourth was 3.9 million while activated T cell count was 4.2 million. When the PB was withdrawn for the fifth transfusion, the NK, T lymphocytes expansions were higher leading to transfusion of a cell count of 103 million and activated T lymphocytes of 329 million. On the whole, the immune cells expansion in this patient was lesser compared to other patients and this can be attributed to the association of AIHA.^\[[@bb10]\]^ Nevertheless there were no adverse effects after the AIET and the patient continues to be stable as per the latest follow-up in August 2012.

Hurdles overcome and lessons learned
====================================

As with translation of any therapy, there were hurdles during the initial translation of the AIET technology from the Biotherapy Institute of Japan to India. As AIET was new to our team of scientists, they were trained initially for two years by the Japanese experts and there is a constant interaction with frequent information exchange among the Indian technical team and the Japanese team till date. The hurdle faced in the use of Laboratory reagents is that their efficacy might vary according to the manufacturer and to put aside the doubt and to ensure that the same results obtained in Japan are reproduced in India, all the laboratory reagents used in India are the same used in Biotherapy institute obtained from Japan. Biotherapy Institute constantly monitors quality of the reagents by assessing their effects on primary cell cultures and cell lines which are maintained in that Institute. The hurdle in infrastructure requirements were overcome by establishing a laboratory in India with similar specifications and equipments as that in Japan with even more stringent protocols to suit the Indian conditions. With these lessons learned in translating the technology of AIET from Japan to India and following the significant outcomes in the various patients mentioned above and more than 60 others, future studies are underway to analyze the methods by which the *in vivo* efficacy of NK cells can be enhanced and analyzing the synergistic effects when AIET is combined with Monoclonal antibodies.

Conclusion
==========

AIET technology was successfully translated from Japan to India overcoming various hurdles and since 2005 several patients in India have been administered AIET with no adverse reactions of any kind, which falls in line with the earlier reports from the literature. Significant increase in disease free survival or static non-progressive disease could be accomplished in patients with ovarian cancer, Acute Lymphoblastic leukemia, Acute Myeloid Leukemia, advanced in-operable pancreatic cancer, prostate cancer with multiple metastasis and breast cancer with metastasis, we have experienced. An increase in awareness about this least toxic method of Cancer treatment among physicians and the public for an early referral is necessary. Further studies on prevention of cancer using *in vitro* expanded autologous immune cells are underway.
